World Heart Federation Cholesterol Roadmap 2022

Imagem de Miniatura
Arquivos
art_RAY_World_Heart_Federation_Cholesterol_Roadmap_2022_2022.PDF (5.01 MB)
Citações na Scopus
47
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
UBIQUITY PRESS LTD
Autores
RAY, Kausik K.
FERENCE, Brian A.
SEVERIN, Tania
BLOM, Dirk
NICHOLLS, Stephen J.
SHIBA, Mariko H.
ALMAHMEED, Wael
ALONSO, Rodrigo
DACCORD, Magdalena
EZHOV, Marat
Citação
GLOBAL HEART, v.17, n.1, article ID 75, 29p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to prevent ASCVD. Advances in current concepts about reducing cumulative exposure to apolipoprotein B (apo B) cholesterol-containing lipoproteins and the emergence of novel therapies provide new opportunities to better prevent ASCVD. The present update of the World Heart Federation Cholesterol Roadmap provides a conceptual framework for the development of national policies and health systems approaches, so that potential roadblocks to cholesterol management and thus ASCVD prevention can be overcome.Methods: Through a review of published guidelines and research papers since 2017, and consultation with a committee composed of experts in clinical management of dyslipidaemias and health systems research in low-and-middle income countries (LMICs), this Roadmap identifies (1) key principles to effective ASCVD prevention (2) gaps in implementation of these interventions (knowledge-practice gaps); (3) health system roadblocks to treatment of elevated cholesterol in LMICs; and (4) potential strategies for overcoming these.Results: Reducing the future burden of ASCVD will require diverse approaches throughout the life-course. These include: a greater focus on primordial prevention; availability of affordable cholesterol testing; availability of universal cholesterol screening for inherited dyslipidaemias; risk stratification moving beyond 10-year risk to look at lifetime risk with adequate risk estimators; wider availability of affordable cholesterol-lowering therapies which should include statins as essential medications globally; use of adequate doses of potent statin regimens; and combination therapies with ezetimibe or other therapies in order to attain and maintain robust reductions in LDL-C in those at highest risk. Continuing efforts are needed on health literacy for both the public and healthcare providers, utilising multi-disciplinary teams in healthcare and applications that quantify both ASCVD risk and benefits of treatment as well as increased adherence to therapies.Conclusions: The adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated to implement health policy, lifestyle changes and when needed pharmacotherapies earlier with investment in, and a shift in focus towards, early preventive strategies that preserve cardiovascular health rather than treat the consequences of ASCVD.
Palavras-chave
cholesterol, low-density lipoprotein cholesterol prevention, ASCVD, lipid lowering therapy, familial hypercholesterolaemia
URI
https://observatorio.fm.usp.br/handle/OPI/50460
Referências
  1. Adler AJ, 2015, GLOB HEART, V10, P111, DOI 10.1016/j.gheart.2015.04.006
  2. Banach M, 2020, JAMA CARDIOL, V5, P1124, DOI 10.1001/jamacardio.2020.2314
  3. Berry JD, 2012, NEW ENGL J MED, V366, P321, DOI 10.1056/NEJMoa1012848
  4. Bhatt DL, 2019, NEW ENGL J MED, V380, P11, DOI 10.1056/NEJMoa1812792
  5. Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180
  6. Blom DJ, 2011, S AFR FAM PRACT, V53, P11, DOI 10.1080/20786204.2011.10874054
  7. Brandts J, 2021, J AM COLL CARDIOL, V78, P1831, DOI 10.1016/j.jacc.2021.09.004
  8. Brandts J, 2021, ATHEROSCLEROSIS, V325, P46, DOI 10.1016/j.atherosclerosis.2021.03.042
  9. Correa VC, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00588-8
  10. De Backer G, 2019, ATHEROSCLEROSIS, V285, P135, DOI 10.1016/j.atherosclerosis.2019.03.014
  11. Deanfield J, 2014, HEART, V100, P1, DOI 10.1136/heartjnl-2014-305693
  12. Delgado-Lista J, 2022, LANCET, V399, P1876, DOI 10.1016/S0140-6736(22)00122-2
  13. Di Angelantonio E, 2019, LANCET GLOB HEALTH, V7, pE1332, DOI 10.1016/S2214-109X(19)30318-3
  14. Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
  15. Ference BA, 2019, JAMA-J AM MED ASSOC, V322, P1381, DOI 10.1001/jama.2019.14120
  16. Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144
  17. Ference BA, 2012, J AM COLL CARDIOL, V60, P2631, DOI 10.1016/j.jacc.2012.09.017
  18. FH Europe, FH EUR POSTT M STAT
  19. Fischer F, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4030036
  20. Gidding SS, 2022, EUR HEART J, V43, P2892, DOI 10.1093/eurheartj/ehac009
  21. Groselj U, 2022, EUR HEART J, V43, P3209, DOI 10.1093/eurheartj/ehac224
  22. Grundy SM, 2019, J AM COLL CARDIOL, V73, P3168, DOI 10.1016/j.jacc.2018.11.002
  23. Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003
  24. Hageman SHJ, 2022, EUR HEART J, V43, P1715, DOI 10.1093/eurheartj/ehac056
  25. Hooper L, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011583.pub2, 10.1002/14651858.CD011737]
  26. Hu PW, 2020, CIRCULATION, V141, P1742, DOI 10.1161/CIRCULATIONAHA.119.044795
  27. Huffman MD, 2014, J AM COLL CARDIOL, V63, P1368, DOI 10.1016/j.jacc.2013.08.1665
  28. Jacobs DR, 2022, NEW ENGL J MED, V386, P1877, DOI 10.1056/NEJMoa2109191
  29. Jaeger BR, 2009, NAT CLIN PRACT CARD, V6, P229, DOI 10.1038/ncpcardio1456
  30. Joseph P, 2021, LANCET, V398, P1133, DOI 10.1016/S0140-6736(21)01827-4
  31. Jousilahti P, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i721
  32. Kaasenbrood L, 2016, CIRCULATION, V134, P1419, DOI 10.1161/CIRCULATIONAHA.116.021314
  33. Kim Byeong-Keuk, 2022, Lancet, V400, P380, DOI 10.1016/S0140-6736(22)00916-3
  34. Kronenberg F, 2022, LIPOPROTEINA ATHEROS, DOI [10.1093/eurheartj/ehac361, DOI 10.1093/EURHEARTJ/EHAC361]
  35. Kumar D, 2021, EUR HEART J, V42, P1413
  36. Laufs U, 2022, J CLIN LIPIDOL, V16, P286, DOI 10.1016/j.jacl.2022.03.001
  37. Lichtenstein AH, 2021, CIRCULATION, V144, pE472, DOI 10.1161/CIR.0000000000001031
  38. Luirink IK, 2019, NEW ENGL J MED, V381, P1547, DOI 10.1056/NEJMoa1816454
  39. Mach F, 2018, EUR HEART J, V39, P2526, DOI 10.1093/eurheartj/ehy182
  40. Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
  41. Malik S, 2017, JAMA CARDIOL, V2, P1332, DOI 10.1001/jamacardio.2017.4191
  42. Marcus ME, 2022, LANCET GLOB HEALTH, V10, pE369, DOI 10.1016/S2214-109X(21)00551-9
  43. Mark L, 2015, ATHEROSCLEROSIS, V241, P62, DOI 10.1016/j.atherosclerosis.2015.04.810
  44. Marston NA, 2022, JAMA CARDIOL, V7, P250, DOI 10.1001/jamacardio.2021.5083
  45. Martin SS, 2013, JAMA-J AM MED ASSOC, V310, P2061, DOI 10.1001/jama.2013.280532
  46. McCrindle BW, 2016, NEW ENGL J MED, V375, P1685, DOI 10.1056/NEJMe1611081
  47. McKay AJ, 2022, EUR J PREV CARDIOL, V29, P654, DOI 10.1093/eurjpc/zwab093
  48. McKay AJ, 2018, ATHEROSCLEROSIS, V275, P434, DOI 10.1016/j.atherosclerosis.2018.05.047
  49. Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5
  50. Mozaffarian D, 2009, EUR J CLIN NUTR, V63, pS5, DOI 10.1038/sj.ejcn.1602973
  51. Mozaffarian D, 2016, CIRCULATION, V133, P187, DOI 10.1161/CIRCULATIONAHA.115.018585
  52. Murphy A, 2017, GLOB HEART, V12, P179, DOI 10.1016/j.gheart.2017.03.002
  53. Nadarajah R, 2022, EUR HEART J, V43, P3164, DOI 10.1093/eurheartj/ehac227
  54. Nasir K, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n776
  55. NCD Alliance, 2019, T FAT FREE 2023 CAS
  56. de Isla LP, 2016, J AM COLL CARDIOL, V67, P1278, DOI 10.1016/j.jacc.2016.01.008
  57. Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106
  58. Raal FJ, 2020, NEW ENGL J MED, V383, P711, DOI 10.1056/NEJMoa2004215
  59. Raal FJ, 2015, LANCET, V385, P341, DOI 10.1016/S0140-6736(14)61374-X
  60. Ray KK, 2022, EUR HEART J, V43, P830, DOI 10.1093/eurheartj/ehab718
  61. Ray KK, 2021, EUR J PREV CARDIOL, V28, P1279, DOI 10.1093/eurjpc/zwaa047
  62. Rittiphairoj T., 2022, STATE CARDIOVASCULAR
  63. Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010
  64. Sajja A, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.28817
  65. Sampson M, 2020, JAMA CARDIOL, V5, P540, DOI 10.1001/jamacardio.2020.0013
  66. Santos RD, 2020, J AM COLL CARDIOL, V75, P565, DOI 10.1016/j.jacc.2019.12.020
  67. Santos RD, 2016, LANCET DIABETES ENDO, V4, P850, DOI 10.1016/S2213-8587(16)30041-9
  68. Sathiyakumar V, 2018, CIRCULATION, V137, P10, DOI 10.1161/CIRCULATIONAHA.117.030677
  69. Sharma S, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0269605
  70. Sturm AC, 2018, J AM COLL CARDIOL, V72, P662, DOI 10.1016/j.jacc.2018.05.044
  71. Szarek M, 2020, EUR HEART J, V41, P4245, DOI 10.1093/eurheartj/ehaa649
  72. Taddei C, 2020, NATURE, V582, P73, DOI 10.1038/s41586-020-2338-1
  73. Taddei C, 2020, INT J EPIDEMIOL, V49, P173, DOI 10.1093/ije/dyz099
  74. Tromp TR, 2022, LANCET, V399, P719, DOI 10.1016/S0140-6736(21)02001-8
  75. Vallejo-Vaz AJ, 2021, LANCET, V398, P1713, DOI 10.1016/S0140-6736(21)01122-3
  76. Vasan RS, 2022, CIRCULATION, V145, P1324, DOI 10.1161/CIRCULATIONAHA.121.057889
  77. Versmissen J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2423
  78. Virani SS, 2022, PROG CARDIOVASC DIS, V73, P32, DOI 10.1016/j.pcad.2022.01.002
  79. Visseren FLJ, 2022, EUR J PREV CARDIOL, V29, P5, DOI [10.1093/eurjpc/zwab154, 10.1093/eurheartj/ehab484]
  80. Wald DS, 2016, NEW ENGL J MED, V375, P1628, DOI 10.1056/NEJMoa1602777
  81. Watanabe JH, 2014, J MANAGE CARE PHARM, V20, P43, DOI 10.18553/jmcp.2014.20.1.43
  82. Watkins DA, 2022, LANCET, V399, P1266, DOI 10.1016/S0140-6736(21)02347-3
  83. Wilemon KA, 2020, JAMA CARDIOL, V5, P217, DOI 10.1001/jamacardio.2019.5173
  84. World Heart Federation, 2021, IMPROVING PREVENTION
  85. Zhu JR, 2018, J GERIATR CARDIOL, V15, P1, DOI 10.11909/j.issn.1671-5411.2018.01.011

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - ODS/03